A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years.

Trial Profile

A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2014

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin suspension isophane
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Lantus-P-CN
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top